## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.5% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($770.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Horiko Capital Management LLC Has $34.65 Million Stock Holdings in McKesson Corporation $MCK**
- Source: MarketBeat | 20251203T041025 | Somewhat-Bullish | Relevance: 99%
-  Horiko Capital Management LLC has decreased its stake in McKesson Corporation by 3.1%, now holding 47,403 shares valued at approximately $34.65 million. McKesson constitutes 9.1% of the fund's holdings, making it their fifth largest position. Analysts generally recommend a "Moderate Buy" for McKesson, with an average price target of $887.69.

**2. Why Is McKesson (MCK) Down 5.2% Since Last Earnings Report?**
- Source: www.sharewise.com | 20251205T182737 | Somewhat-Bullish | Relevance: 98%
-  McKesson (MCK) shares have dropped 5.2% since its last earnings report, underperforming the S&P 500, despite beating EPS estimates for Q2 fiscal 2026. The company's revenues missed expectations, though they grew year-over-year, and McKesson has raised its fiscal 2026 EPS guidance. Estimates for the stock have been broadly trending downward in the past month.

**3. McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025**
- Source: ts2.tech | 20251203T230808 | Bullish | Relevance: 98%
- McKesson Corporation (MCK) experienced a stock price drop of nearly 3% on December 3, 2025, closing at $805.37, despite being a strong performer in U.S. healthcare throughout the year. The pullback is attributed to profit-taking, institutional portfolio adjustments, and investors processing new guidance and oncology initiatives. The company is actively reshaping its portfolio by spinning off its Medical-Surgical Solutions segment and focusing on oncology, specialty drugs, and tech-enabled services, with analysts generally bullish on its long-term prospects.

**4. Invesco Ltd. Has $689.33 Million Stock Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251204T120834 | Somewhat-Bullish | Relevance: 98%
-  Invesco Ltd. reduced its stake in McKesson Corporation by 11.4% in Q2, now holding 940,708 shares valued at $689.33 million, though institutional ownership remains high at 85.07%. Analysts maintain a "Moderate Buy" rating with a consensus target price of $887.69, following positive Q3 earnings where McKesson beat estimates with $9.86 EPS. The company also declared a quarterly dividend of $0.82, and insider selling activity was noted with the CAO reducing their shares by 50.08%.

**5. Portfolio Design Labs LLC Takes $4.57 Million Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251203T011001 | Bullish | Relevance: 98%
-  Portfolio Design Labs LLC initiated a new position in McKesson Corporation (NYSE:MCK) during the second quarter, acquiring 6,238 shares valued at approximately $4.57 million. This investment makes McKesson the firm's 27th largest holding, constituting about 0.9% of its total portfolio. McKesson recently reported strong Q2 earnings, surpassing EPS estimates while revenue slightly missed forecasts, and announced a quarterly dividend of $0.82 per share.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |
| 2025-11-10 | Wells Fargo | $914 | $816 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |
| 2025-11-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Analyst sentiment positive (1 raises, avg +12%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $98.9B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.5 |
| Current P/E | 20.9 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -3.2% to -6.5% (-3.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.5pp (needs >3.0% for momentum thesis). Underperforming sector by 4.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-10.15), momentum weakening. RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.50% (CS: 3) | Weak |
| RSI_14 | 41.0 | Neutral |
| MACD Histogram | -10.15 | Bearish |
| vs SMA20 | 0.950x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $808.62
- **Stop Loss:** $770.06 (4.8% risk)
- **Target:** $847.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $9,703.44
- **Portfolio %:** 9.70%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*